Do inflammatory cytokines impair insulin signaling and increase production of triglyceride-rich lipoproteins?

The relationship between chronic low-grade inflammation, insulin signaling, and lipid metabolism is a well-established pathological axis. Scientific evidence confirms that inflammatory cytokines are primary drivers of systemic insulin resistance and the subsequent overproduction of triglyceride-rich lipoproteins (TRLs).

Mechanistic explanations

Inflammatory cytokines, specifically tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and IL-1β, impair insulin receptor signaling by activating pro-inflammatory kinases such as c-Jun N-terminal kinase (JNK) and IκB kinase-β (IKK-β). These kinases catalyze the inhibitory serine phosphorylation of insulin receptor substrate 1 (IRS-1), which prevents the essential tyrosine phosphorylation required for insulin-stimulated PI3K/Akt activation. Furthermore, IL-6 can upregulate Suppressor of Cytokine Signaling-3 (SOCS-3), which promotes the ubiquitination and degradation of IRS-1. This signaling blockade directly reduces GLUT4 translocation to cell membranes, significantly impairing glucose disposal and defining the state of insulin resistance.

Impact on triglyceride-rich lipoproteins

In the liver, insulin normally acts as a "brake" on the production of TRLs, primarily Very Low-Density Lipoproteins (VLDL). This is achieved by promoting the degradation of apolipoprotein B (apoB) and suppressing microsomal triglyceride transfer protein (MTP). In insulin-resistant states, this suppression is lost. Additionally, dysregulated signaling leads to the hyperactivation of SREBP-1c and the accumulation of FoxO1, which upregulate enzymes for triglyceride synthesis. Stable isotope tracer studies demonstrate that insulin-mediated suppression of VLDL-triglyceride secretion is markedly less effective in insulin-resistant subjects (e.g., a 22% reduction compared to a 56% reduction in lean controls), leading to the characteristic elevation of circulating triglycerides.

Bottom line

The claim is strongly supported by science. Inflammatory cytokines impair the IRS-1/PI3K/Akt signaling cascade, leading to systemic insulin resistance and a significant increase in the hepatic production and secretion of triglyceride-rich VLDL particles.